|Description||Ruxolitinib is a potent and selective JAK1/2 inhibitor with IC50 values of 3.3 nM and 2.8 nM respectively in cell-free assays, and has > 130-fold selectivity for JAK1/2 versus JAK3.|
|B0084-156872||200 mg||$198||In stock|
|B0084-156872||500 mg||$398||In stock|
|Appearance||White to Off-white Solid|
|Synonyms||(R)-Ruxolitinib; INCB018424; R-INCB018424; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile|
TYK2-IN-2 is an inhibitor of TYK2 with potential for the treatment of inflammatory and autoimmune diseases.
Cyt387, also called Momelotinib, under the IUPAC name N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide, is an ATP competitive inhib...
This active molecular is a novel Janus Kinase 3 (JAK3) inhibitor. CP-690550A is an immunosuppressant for the treatment of rheumatoid arthritis, psoriasis, trans...
Itacitinib is a potent Janus kinase-1 inhibitor under the development of AstraZeneca and Incyte Corporation. Itacitinib can inhibit OCT2-mediated uptake of crea...
Pacritinib, also known as SB1518, is an orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic acti...
Peficitinib, also known as ASP015K and JNJ-54781532, is a novel potent JAK inhibitor, which demonstrated potent efficacy in adjuvant-induced arthritis model in ...
Oclacitinib, also known as PF03394197, is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. Oclacitinib inhibited JAK family m...
WHI-P97 is a potent cell-permeable and specific inhibitor of JAK3(IC50 = 11 μM). Inhibits JAK3 in immune complex kinase assaysin a dose-dependent fashion and re...